Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 12/20 | 0.56 |
| ▸ | PRKCI | P41743 | 1/20 | 0.54 |
| ▸ | ATR | Q13535 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PRKDC | P78527 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4559784 | 0.81 | PTPN11 (0.48) | PTPN11PRKCIATRMEN1ALDH1A1 | |
| SCHEMBL11298985 | 0.81 | PTPN11 (0.63) | PTPN11PRKCIATRMEN1ALDH1A1 | |
| SCHEMBL6582057 | 0.77 | PTPN11 (0.59) | PTPN11PRKCIATRMEN1ALDH1A1 | |
| SCHEMBL560665 | 0.76 | ATR (0.65) | ATRPRKDC | |
| SCHEMBL22573544 | 0.76 | LMNA (0.64) | PTPN11PRKCIATRMEN1ALDH1A1 | |
| SCHEMBL22573444 | 0.73 | PRKCI (0.58) | PTPN11PRKCIATRMEN1ALDH1A1 | |
| SCHEMBL22573364 | 0.72 | ATR (0.61) | PTPN11PRKCIATRMEN1ALDH1A1 | |
| SCHEMBL22573851 | 0.72 | LMNA (0.70) | PTPN11PRKCIATRMEN1ALDH1A1 | |
| SCHEMBL22573773 | 0.72 | LMNA (0.62) | PTPN11PRKCIATRMEN1ALDH1A1 | |
| SCHEMBL22573566 | 0.72 | ATR (0.61) | PTPN11PRKCIATRMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | PTPN11 1278/4885PRKCI 4336/4885ATR 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.